Chemomab Therapeutics (CMMB) Total Liabilities (2017 - 2025)

Chemomab Therapeutics (CMMB) has 9 years of Total Liabilities data on file, last reported at $1.5 million in Q4 2025.

• For the quarter ending Q4 2025, Total Liabilities fell 56.87% year-over-year to $1.5 million; the trailing twelve-month figure through Dec 2025 stood at $1.5 million (down 56.87% YoY), and the FY2025 full-year result was $1.5 million, down 56.87% from the prior year.
• Total Liabilities for Q4 2025 stood at $1.5 million, up from $1.1 million in the prior quarter.
• Across five years, Total Liabilities topped out at $7.1 million in Q1 2023 and bottomed at $1.1 million in Q3 2025.
• The 5-year median for Total Liabilities is $4.6 million (2022), against an average of $4.1 million.
• The widest annual swing landed in 2022, when Total Liabilities surged 190.2%; it then tumbled 75.17% in 2025.
• A 5-year view of Total Liabilities shows it stood at $2.9 million in 2021, then soared by 136.92% to $6.8 million in 2022, then declined by 24.65% to $5.2 million in 2023, then tumbled by 33.51% to $3.4 million in 2024, then plunged by 56.87% to $1.5 million in 2025.
• The last three Total Liabilities figures came in at $1.5 million (Q4 2025), $1.1 million (Q3 2025), and $1.4 million (Q2 2025), per Business Quant data.

Peer Comparison